The #FDA released a statement today ALERTING laboratory personnel and healthcare providers about #Illumina cybersecurity vulnerabilities. Illumina supplies the majority of genomic laboratories with instrumentation to sequence DNA. The letter to healthcare providers discusses that a user may operate the technology for both clinical diagnostic use or research purposes.  Ultimately the following is the most important information presented:

The cybersecurity vulnerability affects the Local Run Manager (LRM) software. An unauthorized user could exploit the vulnerability by:

#CenterForGenomicInterpretation appreciates the #FDA staying on top of cybersecurity events that could impact patient test results.

Labs should contact Illumina, if they didn’t receive a notification for a temporary patch until a permanent fix is found. techsupport@illumina.com